137 related articles for article (PubMed ID: 38157806)
21. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
23. Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
Yang J; Huang J; Yuan G; Lin XC; Chen HJ; Yang JJ
Clin Case Rep; 2024 Jun; 12(6):e8866. PubMed ID: 38799516
[TBL] [Abstract][Full Text] [Related]
24. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
25. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
26. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
27. Sotorasib for previously treated colorectal cancers with KRAS
Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
[TBL] [Abstract][Full Text] [Related]
28. Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
Jiang Y; Zhao M; Liu R; Zheng X
Medicine (Baltimore); 2023 Dec; 102(50):e36387. PubMed ID: 38115313
[TBL] [Abstract][Full Text] [Related]
29. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
30. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract][Full Text] [Related]
31. Adagrasib in Advanced Solid Tumors Harboring a
Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
[TBL] [Abstract][Full Text] [Related]
32. CodeBreak 200: Sotorasib Has Not Broken the KRAS
Zhang SS; Lee A; Nagasaka M
Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
[TBL] [Abstract][Full Text] [Related]
33. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
Brazel D; Nagasaka M
Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
[TBL] [Abstract][Full Text] [Related]
34. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
35. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
[TBL] [Abstract][Full Text] [Related]
37. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
Brazel D; Kim J; Ou SI
Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M;
Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369
[TBL] [Abstract][Full Text] [Related]
39. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.
Frost MG; Jensen KJ; Gotfredsen DR; Sørensen AMS; Ankarfeldt MZ; Louie KS; Sroczynski N; Jakobsen E; Andersen JL; Jimenez-Solem E; Petersen TS
Lung Cancer; 2023 Apr; 178():172-182. PubMed ID: 36868178
[TBL] [Abstract][Full Text] [Related]
40. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
